Skip to content

Perbak Capital Partners LLP: EXLS position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Perbak Capital Partners LLP on EXLS, newest first. How the timeline and the estimate are built.

Perbak Capital Partners LLP held 0 EXLS shares at 2026-06-30 per its 13F-HR filed 2026-08-14.

the latest 13F is the newest step

  1. period ended2026-06-30
    13F 0 shares
    Change vs previous 13F -27,995 shares

    13F-HR 0000902664-26-003476 filed by Perbak Capital Partners LLP
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

    Exited: the 13F for this period no longer lists the position.

  2. period ended2026-03-31
    13F 27,995 shares
    Change vs previous 13F +18,856 shares

    0.21% of the 13F portfolio, value $852,448.

    13F-HR 0000902664-26-002476 filed by Perbak Capital Partners LLP
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2025-12-31
    13F 9,139 shares
    Change vs previous 13F -16,774 shares

    0.12% of the 13F portfolio, value $387,859.

    13F-HR 0000902664-26-001029 filed by Perbak Capital Partners LLP
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2025-09-30
    13F 25,913 shares
    Change vs previous 13F +15,706 shares

    0.2% of the 13F portfolio, value $1,140,949.

    13F-HR 0000902664-25-004905 filed by Perbak Capital Partners LLP
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2025-06-30
    13F 10,207 shares
    Change vs previous 13F not available

    0.1% of the 13F portfolio, value $446,965.

    13F-HR 0000902664-25-003680 filed by Perbak Capital Partners LLP
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).